% | $
Quotes you view appear here for quick access.

People's United Financial Inc. Message Board

hrly_needs_passenger 2 posts  |  Last Activity: Jun 30, 2016 1:12 PM Member since: May 24, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • “The clinical and pharmacokinetic profile of GALE-401 has shown that by reducing the maximum plasma concentration (Cmax) of anagrelide with our controlled release version, GALE-401 seems to confer an improved overall safety profile and potentially offers an improved tolerability compared to the approved product,” said Bijan Nejadnik, M.D., Executive Vice President and Chief Medical Officer. “Overall, in our Phase 2 study, we observed predominantly mild to moderate toxicities that did not reveal any unexpected AEs, and we are encouraged by the results as it relates to patients who were previously intolerant to anagrelide IR who were able to continue their treatment with GALE-401 for a meaningful longer duration. Given this data, we plan to meet with the FDA later this year to discuss the next stages of development for the asset.”

    Sentiment: Buy

  • Brilliant minds ,Enjoy the ride ,going back up soon

    Sentiment: Buy

15.81-0.04(-0.25%)Sep 23 4:00 PMEDT